News Quantified

ALPMY – astellas pharma unsp/adr (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Astellas Pharma (ALPMY) was upgraded by Jefferies Financial Group Inc. from "hold" to "strong-buy".

IsomAb appoints Dr Philip Brainin as Chief Executive Officer [Yahoo! Finance]

JAMP Pharma Group Expands Oncology Portfolio with PrJAMP Enzalutamide [Yahoo! Finance]

BioNTech's Founding Duo Will Leave to Start New mRNA Firm [Yahoo! Finance Canada]

BioNTech's Founding Duo Will Leave to Start New mRNA Firm [Yahoo! Finance]

Top News Gainers

4/9 Astellas Announces Acceptance of XOSPATA® (gilteritinib) for Regulatory Review in China by the National Medical Products Administration 3.4%

12/17 FDA OKs expanded use of Astellas and Pfizer's Xtandi [Seeking Alpha] 2.5%

8/6 Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms 2.4%

10/30 Pandion and Astellas Announce Collaboration to Deliver Pancreas-Targeted Immunomodulators 1.8%

12/5 Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science 1.5%

1/23 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock. 1.3%

9/20 Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation 1.0%

7/10 Astellas Appoints Chelsea Glinski as National Vice President Oncology Sales 0.6%

1/15 Astellas Completes Acquisition of Audentes Therapeutics 0.3%

1/31 UPDATE 2-Astellas Pharma keeps profit forecast as prostate cancer drug sales rise [Reuters] 0.2%

Top News Decliners

5/30 U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib) -3.8%

2/11 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -3.6%

10/1 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -1.7%

7/31 Q1/2019 6/30/2019 EPS 35.580 ZacksConsensus N/A ActVsEst N/A - N/A -1.4%

11/20 Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics -1.3%

10/1 Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy -1.3%

9/11 Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts -1.3%

3/26 ASTELLAS PHARMA/ADR (OTCMKTS: ALPMY) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -1.1%

5/20 Astellas Oncology Announces C³ Prize® Call for Entries to Award $200,000 to the Best Ideas in Cancer Care Beyond Medicine -0.9%

7/31 Q1/2019 6/30/2019 EPS 35.580 ZacksConsensus N/A ActVsEst N/A - N/A -0.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day